# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst Richard Law initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announces ...
Oppenheimer analyst Matthew Biegler reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and maintains $21 price...
HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price t...
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate ...
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday.
-S-3
Citigroup analyst Yigal Nochomovitz initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announce...
Although U.S. stocks closed mostly higher on Monday, there were a few notable insider trades.